Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report

Fig. 2

Changes in the liver enzymes, body weight and IGF-1 after the initiation of hormone replacement and anti-RANKL antibody. After the replacement of hydrocortisone 5 mg/day and oral desmopressin 30 μg/day, the liver enzymes were unchanged. Three months later anti-RANKL antibody 60 mg was administered, and plasma levels of ALT and γGTP were decreased from 133 to 62 U/L and from 284 to 171 U/L, respectively. Reduction of liver enzymes was also confirmed after second and third administration of anti-RANKL antibody. GH and levothyroxin replacement were initiated between the second and the third administration of anti-RANKL antibody, and IGF-1 level was increased to normal range. However, the liver enzymes were not decreased by replacement with GH and levothyroxin. She gained 6.1 kg of weight during the treatment period

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us